ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.53
-0.04 (-1.56%)
As of 11:21AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.57
Open2.60
Bid2.52 x 900
Ask2.54 x 1300
Day's Range2.52 - 2.61
52 Week Range2.20 - 5.10
Volume80,007
Avg. Volume897,353
Market Cap119.647M
Beta (3Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-0.98
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
    Zacks5 days ago

    Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates

    Adamis (ADMP) delivered earnings and revenue surprises of -40.00% and -28.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 days ago

    Adamis: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire5 days ago

    Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update

    SAN DIEGO, Nov. 09, 2018 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2018 and a business.

  • Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks8 days ago

    Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswirelast month

    Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.last month

    Could Adamis Pharmaceuticals Corporation’s (NASDAQ:ADMP) Investor Composition Impacts Your Returns?

    A look at the shareholders of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...

  • GlobeNewswire2 months ago

    Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi ™ for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Symjepi (epinephrine) Injection 0.3mg is an FDA-approved product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis, designed for patients weighing 66 pounds or greater. The lower dose version (0.15mg) is intended to potentially treat patients weighing 33-66 pounds.  Both Symjepi products will provide two single-dose injections syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to allergic reaction to foods (such as nuts), insect stings or bites, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis.

  • Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
    Zacks2 months ago

    Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher

    Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

  • ACCESSWIRE2 months ago

    Adamis Pharmaceuticals, FDA PDUFA Action Anticipated, Analyst Coverage

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adamis Pharmaceuticals Corporation (ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease and allergy. The company's Symjepi (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and its Symjepi (epinephrine) Injection 0.15mg product is undergoing FDA review. ADMP has selected Novartis unit Sandoz to launch the product in the U.S. (the FDA approved the 0.30 mg version in November 2017).

  • Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

  • GlobeNewswire3 months ago

    Adamis Pharmaceuticals Provides Business Update

    SAN DIEGO, Aug. 27, 2018-- Adamis Pharmaceuticals Corporation today provided a business update.. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said,“ We have been receiving ...

  • Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead
    Market Realist3 months ago

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    Mylan’s (MYL) epinephrine auto-injector EpiPen is approved as the first line of treatment for life-threatening allergic reaction anaphylaxis. During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

  • Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
    Zacks3 months ago

    Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

    Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Biotech stocks Antares Pharma rose marginally and Adamis Pharmaceuticals was in the red on Thursday after news of Teva receiving FDA approval for its generic version of the EpiPen. Antares Pharma, Inc. shares closed up 4.10% on Thursday with an additional 3.33% in gains in after-hours trading. The company announced yesterday that it's partner Teva Pharmaceutical Industries has had its epinephrine auto injector drug-device combination product for emergency treatment of severe allergic reactions, approved by the Food and Drug Administration.

  • FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%
    Market Realist3 months ago

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Today, Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr. The epinephrine autoinjector is used to treat allergic reactions, including life-threatening condition of anaphylaxis. The company received FDA approval for the use of the product in adults as well as children weighing more than 33 pounds. In 2016, Teva’s generic version of EpiPen was unable to secure FDA approval.

  • MarketWatch3 months ago

    FDA approves first rival generic EpiPen, sending Teva shares up 6%

    Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. (TEVA) surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector. Shares of Mylan (MYL) , which sells the EpiPen and a cheaper authorized generic version, slumped 0.5% in heavy trade, while rivals Amneal Pharmaceuticals Inc. (AMRX) and Adamis Pharmaceuticals Corp. (ADMP) had shares drop 3% and 7.5% respectively.

  • Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates

    Adamis (ADMP) delivered earnings and revenue surprises of -70.59% and -5.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Adamis: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 29 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...